Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody campath‐1h administered by daily subcutaneous injection

Abstract

C1H is a lymphocyte-depleting antibody that exhibits biologic potency when administered subcutaneously to patients with refractory RA. Its use is associated with mild to moderate toxicity and short-term amelioration of disease activity.